IntelGenx Technologies Corp (IGXT)

[whatisthecolorofmone]

DD (copied)

IGXT.OB
Industry: Bio-technology
Market Capitalization: 24,936,201
Outstanding Shares: 39,581,272
Listing Exchanges: OTCQB as IGXT and Toronto Ventrue Exchange: IGX
Current price: $.074

Investment Highlights
- NDA re-submission to FDA this week (week May 16, 2011, for details clik the Q1 reports link below)
- CPI-300 (Antidepressant) may be approved by FDA in early 3Q 2011 .CPI-300 will be the only "once a day 450g pill" on the Market sales could reach 300 Mil$ per year .
- "Wellbutrin XL® Tablets, 150 mg, marketed by GlaxoSmithKline, had U.S. sales of approximately $930 million "
-Major Partnership for CPI-300 coming any time now upfront payments could be much higher than current market cap of 24 million .
- Intelgenx has a very attractive product pipeline (10 products) including a Blockbuster (THC Drug).
-
IntelGenx Corp. (IGXT.OB) Hits Milestone with VersaFilm Oral Thin Film Technology
- Instituion hold 20%
(for details click the link below)
http://data.cnbc.com/quotes/IGXT.OB/tab/8
- CEO holds 11 M Shares
- Insider buying; directors recently bought massive shares at $0.59
http://canadianinsider.com/coReport/allTransactions.php?ticker=igx
Why IGXT is a Sleeping Giant
This Buy Recommendation was out before Intelgenx wins lawsuit against Biovail means the price target of 2.20 is now way too low for this sleeping giant.
Developments
Intelgenx has announced that they have been issued a patent by the U.S. Patent office (USPTO) for CPI-300, their sustained release, high dose (450 mg) formulation of Bupropion HCl (Wellbutrin).
Impact
Positive. This solidifies Intelgenx as the company all current sellers of Bupropion HCl have to negotiate with if they would like the advantage of having a single dose pill.
Comments
The issuance of this patent puts Intelgenx in the position of having the only approved sustained release, high dose one pill version of Bupropion HCL. This is very attractive to many existing sellers of generic Wellbutrin for several reasons:
1. Doctors start patients at lower doses and then titrate them to higher doses. The compliance is higher when patients take 1 pill versus 2 to 3 pills.
2. Intelgenx uses their proprietary VersaTab technology which can be produced at a significantly lower cost, making the product more price competitive and profitable at the same time.
Intelgenx received a complete response letter from the FDA on February 8th, 2010, which provided 2 areas that Intelgenx must address before approval:
1. Commercial manufacturing site: Intelgenx has hired Pillar5 to be their manufacturer and is now running the necessary batches to gain FDA manufacturing approval. This is done.
2. Food Effect: The Company believes that this can be addressed through a label adjustment and a postapproval educational effort. The food effect was observed both in CPI-300 and the reference product (Wellbutrin). Intelgenx believes that they will have this issue resolved with the FDA in time for an H1/2010 filing and a possible H2/2011 approval.
The patent issued by the USPTO strengthens Intelgenx’s position regarding any possible new entrants with a similar dosage and puts them in a strong negotiating position for a commercialization partnership.
Valuation and Recommendation
Intelgenx has strengthened their negotiating position and is getting substantially closer to commercializing their first major product. A successful approval and launch of CPI-300 will be a substantial revenue opportunity for Intelgenx and will be strong proof of their technology and business model. This will greatly increase the value of Intelgenx’s substantial 10 product pipeline. Speculative price target Tgt $2.20
Mega Pipeline:
http://www.intelgenx.com/products/pipeline.html
Q1 Reports
http://www.marketwire.com/press-release/intelgenx-reports-q1-2011-results-and-highlights-recent-developments-tsx-venture-igx-1512895.htm

------

2. A lot of Upcoming Milestones //Time to get in !!!

IGXT is still flying under Radar but this will change once they submit the NDA next Week means NOW is the best entry point !

I think double digits is very possible within 2 years .IGXT has fantastic Products with very large Market Potential .

I like this Company because the Management is doing a great job ,Cash burn of 300-500k per Month is very low and they have NO DEBT .


Slide Presentation 2011
http://www.intelgenx.com/_assets/pdf/Pre...

Milestones 2011 :

FDA Approval CPI300
CPI300 Launch
Three Regulatory Submissions
Five New Licensing Deals


Milestones 2012:

Two Products Launched
Three New Licensing Deals
Three Regulatory Submissions
INT0010 Successful Phase II/III


Milestones 2013:

Three Products Launched
Two Regulatory Submissions
Three New Licensing Deals

3. IGXT: .92 TO 1.04 POSSIBLE: CHART

Our Indicators are Flashing a Signal Here:

Consolidation before expansion here

based on some mathematical extensions we use, we see a range of .92 to 1.04 possible near term

there is overhead resistance based on gann and Fib at .818 thru .88

about to clear range in both price and time which means it will be trending..

bull flags/pennants very bullish

multiple rotations up possible..

Look for higher prices from here..
GLTA

Want More Alerts From Us? They’re Free.. Including Free Video Analysis!

27 Years of Wall Street Experience .This is all we do!

Take the Challenge..

Join Now Totally FREE: www.TheChartMan.net

New Alert COMING THIS WEEKEND THAT WILL BLOW YOU AWAY.. PROMISE

Where money makes money and the money that money makes, makes more money!
Contact us thru the site, ask us about any stock you own!

IF YOU ARE ANTI BIG, BLOATED GOVERNMENT AND PRO AMERICAN BUSINESS,
YOU NEED TO JOIN US